Shares Investor Evening (London) - LIVE EVENT - 17 July 2024

Cohort, Custodian Property Income REIT, Pathfinder Minerals Plc and Verici Dx

Join Shares and AJ Bell for an evening of investment inspiration and get to meet the decision-makers.

The event on Wednesday 17 July in London will include:

• An opportunity for you to talk directly with the directors and ask your questions about the companies core strengths and their short and long-term business strategy

• Meet fellow investors and share your investing experience

• Complimentary drinks and snacks

More about the companies presenting:

Cohort (AIM: CHRT) is the parent company of six innovative, agile and responsive defence technology businesses providing a wide range of services and products for UK and international customers. It has headquarters in Reading, Berkshire and employs in total over 1,100 core staff there and at its other operating company sites across the UK, Germany, and Portugal. Cohort was admitted to Londons Alternative Investment Market in March 2006.

Custodian Property Income REIT (CREI) offers investors the opportunity to access a diversified portfolio of UK commercial real estate through a closed-ended fund that seeks to provide an attractive level of income and the potential for capital growth

Pathfinder Minerals Plc (PFP) is a natural resources company is being admitted to AIM following the acquisition of Rome Resources Limited in a reverse takeover. Rome Resources holds tin assets in the DRCongo with encouraging initial drilling results, situated only 8km from the highest grade tin mine in the world.

Verici Dx (VRCI) is developing a complementary suite of proprietary, leading-edge tests forming a kidney transplant diagnostics platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence (AI) assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage.